- Press here for the Final Program (Pdf Format)
11.SEPT.2025
| THURSDAY 11th SEPTEMBER 2025 | |
 |
|
| 13:00-18:00 | Registration Desk Open |
|
|
|
| Meeting Rooms 1 & 2, Mezzanine Floor | |
| 13:00-13:30 | ENTIS Board |
| 13:30-14:00 | Scientific Committee Meeting |
| 14:00-14:30 | ENTIS-ConcePTION Steering Committee Meeting |
| 14:30-15:00 | ENTIS Digital (Website) Committee Meeting |
|
|
|
| 15:00-15:30 | Coffee Break |
|
|
|
| Auditorium I, Ground Floor | |
| 15:30-17:30 | ENTIS Business Meeting |
| Moderators: Sally Stephens & Mati Berkovitch | |
|
|
|
| Auditorium I, Ground Floor | |
| 17:30-18:00 | - Lessons from the ConCEPTION Project & other Collaborative Research Projects |
| - Project ConcePTION | |
|
Dr Maya Berlin |
|
| Tel Aviv, Israel | |
| - MADAM: Model Adjusted Doses for ALL Mothers | |
| Miranda (MHM) van Tuyl | |
| Noord-Brabant, Nederland | |
| Moderator: Jonathan Luke Richardson | |
|
|
|
| 18:00-21:00 | Thessaloniki Tour |
|
|
|
| * Coffee Breaks & Light Lunches will take place at Mezzanine Floor (Deck, Mezzanine Floor) | |
|
|
|
12.SEPT.2025
| FRIDAY 12th SEPTEMBER 2025 | |
|
|
|
| 08:30-17:30 | Registration Desk Open |
|
|
|
| Auditorium I, Ground Floor | |
| 08:50-09:00 | Conference Opening |
| Prof. Matitiahu Berkovitch, ENTIS President | |
| Prof. Chrysanthi Sardeli, Welcome from the Local Organizing Committee - Housekeeping | |
|
|
|
| Auditorium I, Ground Floor | |
| 09:00-10:30 | Paternal Exposures & reproductive outcomes (Round Table) |
| - Paternal metformin and major congenital malformations: don’t spook the horse | |
| Professor Per Damkier | |
| Odense, Denmark | |
| - Paternal exposures & pregnancy outcomes - the case of valproate | |
| Professor Jakob Christensen | |
| Aarhus, Denmark | |
| - Effect of paternal MTX exposure on male fertility and birth outcomes. What is known so far? | |
| Dr Corinna Weber-Schoendorfer | |
| Berlin, Germany | |
| Moderator: Marleen van Gelder | |
|
|
|
| 10:30-11:00 |
Coffee break |
|
|
|
| Auditorium I, Ground Floor | |
| 11:00-11:45 | Risk Assessment of Medicinal Products on Human Reproduction and Lactation: from Data to Labelling |
| Dr Raffaella Butera | |
| Pavia/Bergamo, Italy | |
| Moderator: Alice Panchaud | |
|
|
|
| Mezzanine Floor | |
| 11:45-13:00 | Poster Session |
|
P1. Pragmatic and Contextualized Methods Selection for Safety Assessment of Infant Systemic Exposure Through Human Milk: The Milk4baby Decision Tree Anaëlle Monfort P2. Developing a Search Strategy to Assess Safety of Medications during Pregnancy and Lactation Elizabeth Uleryk P3. The use of risk medication during pregnancy: data from the Dutch Pregnancy Drug Register Veronique Y.F. Maas P4. Intravitreal Aflibercept Exposure During Early Pregnancy: Analysis of two cases Aylin Toplu P5. Training Strategies for Caregivers of Adults with Neurological Disorders: Integrating Occupational Therapy and Psychological Support Myrto Patagia Bakaraki P6. Evaluation of exposures of glucagon-like peptide-1 receptor agonists during pregnancy: Case series from a university’s teratology information service Berna Özen P7. Sibling and non-sibling designs in studies investigating the risk of drug exposure during pregnancy: same results? A preliminary meta-epidemiological study Cyndie Picot P8. First trimester exposure to piracetam: A report of four cases Deniz Karagülle P9. Hypersensitivity reactions to parenteral iron in pregnant women and fetal consequences Emilie Vittaz P10. Retrospective study on drug exposure during pregnancy and associated neonatal outcomes in mothers with cardiac diseases Emmanuel Gachiniard P11. High dose ulipristal exposure in the first trimester: a case report Ersan Horoz P12. Cognitive development in children exposed to maternal treatment with selective serotonin reuptake inhibitors during pregnancy and breastfeeding Essi Whaites Heinonen P13. Evaluation of prenatal exposures in congenital heart defects in Rio Grande do Sul, Brazil Fabyanne G. de Oliveira P14. ADHD During Pregnancy and the First Postpartum Year– A Survey Among Norwegian Women Gro C. Havnen P15. High-dose Vitamin D Eggs in Norway: Coordinated Response and Guidance for Pregnant and Breastfeeding Women Gro C. Havnen P16. Associations Between Maternal Prepregnancy Body Mass Index and Maternal and Cord Blood Metabolome Heidi K. Sormunen-Harju P17. Lisdexamfetamine use during lactation - Clinical follow-up of 17 exposed infants Ingrid Alvarez P18. Understanding Real-World Concerns and Information Needs on Medication Use During Pregnancy and Lactation in Japan: A Web-Based Survey to Support Future Evidence Generation Izumi Fujioka P19. Lyell syndrome in pregnancy: A case report Georgios Eleftheriou P20. New Frontiers in Clinical Toxicology. The connection through toxicology and teratology Georgios Eleftheriou P21. Ocrelizumab use before pregnancy and neonatal B-cell depletion. A case report Georgios Eleftheriou P22. The Use of Newly Marketed Drugs During Pregnancy and Lactation: The FARVIGRAL Project Georgios Eleftheriou P23. Benzodiazepines exposure during pregnancy: systematic review and meta-analysis of observational studies Judith Cottin P24. A multidisciplinary Consultation Meeting for the Management of Pregnant or Pregnancy-Planning Epileptic Patients Judith Cottin P25. Acceptance, comprehensibility and impact of embryotox.de in routine healthcare Katarina Dathe P26. Oropouche (Sloth) Fever as a possible new human teratogen Lavinia Schuler-Faccini P27. Association between in utero exposure to acetaminophen and external genital tract malformations in boys and girls: a systematic review and meta-analysis L. Eletri P28. The information system FREIA, a unique work tool to optimize fetal drug safety during pregnancy Line Kolding P29. An exploratory linkage and disproportionality analysis of national congenital anomaly and primary care dispensing data in the UK Jonathan L. Richardson P30. Exposure to monoclonal antibodies during pregnancy and lactation – a growing concern Maja Ratajczak-Enselme P31. Leflunomide exposure in pregnancy: always some uncertainty, a case report that raises questions Marie-Andrée Thompson-Bos P32. Descriptive Analysis of Folate Supplementation Patterns and RBC Folate Levels in Women of Reproductive Age in a Brazilian Hospital Marília K. Rockenbach P33. Asthma medication use before and during pregnancy: guidelines versus multinational practice Marleen M.H.J. van Gelder |
|
| Moderators: Brian Cleary & Jonathan Luke Richardson | |
|
|
|
| 13:00-14:00 | Lunch break |
|
|
|
| Auditorium I, Ground Floor | |
| 14:00-16:00 | Human reproduction and the environment (Round Table) |
| - Outdoor air pollution effects on fertility and pregnancy outcomes: an epidemiological approach | |
| Dr Bénédicte Jacquemin | |
| INSERM, France | |
| - Natural and medical ionizing radiation effects on human fertility and pregnancy | |
| Dr Emmanouil Papanastasiou | |
| Thessaloniki, Greece | |
| - Pharmaceuticals and other contaminants in the aquatic and non-aquatic environment | |
| Professor Alistair Boxall | |
| York, UK | |
| - Endocrine disruptors & their effects on human reproduction | |
| Professor Georgios Mastorakos | |
| Athens, Greece | |
| Moderators: Benoit Marin & Herbert Juch | |
|
|
|
| 16:00-16:30 | Coffee break |
|
|
|
| Auditorium I, Ground Floor | |
| 16:30-17:15 | Prenatal Folate Supplementation – Is there a risk for increased incidence of childhood cancer? |
| Professor Julie Werenberg Dreier | |
| Aarhus, Denmark | |
| Moderator: Mine Kadıoğlu-Duman | |
|
|
|
| Auditorium I, Ground Floor | |
| 17:15-18:00 | OTIS Lecture |
| Studies of OTIS/Mother-to-baby: an update | |
| Professor Christina Chambers | |
| San Diego, California, USA | |
| Moderator: Orna Diav-Citrin | |
|
|
|
| * Coffee Breaks & Light Lunches will take place at the Mezzanine Floor (Patio, Mezzanine Floor) | |
|
|
|
|
Place: Tellogleion Foundation of Arts |
|
| 20:00-22:00 | Welcome Reception |
|
|
|
13.SEPT.2025
| SATURDAY 13th SEPTEMBER 2025 | |
|
|
|
| 08:30-17:30 | Registration Desk Open |
|
|
|
| Auditorium I, Ground Floor | |
| 09:00-10:30 | - Neonatal abstinence syndrome: an update |
| Dr. Georgios Eleftheriou | |
| Bergamo, Italy | |
| - Recreational drug toxicity in Europe: insights from the Euro-DEN Plus Project | |
| Professor Paul I. Dargan | |
| President of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), London, UK | |
| Moderators: Alessandra Pistelli & Marco de Santis | |
|
|
|
| 10:30-11:00 | Coffee break |
|
|
|
| Auditorium I, Ground Floor | |
| 11:00-11:45 | Taking a nuanced approach to biologics in pregnancy (State of the Art Lecture) |
| Dr Ken Hodson | |
| Newcastle upon Tyne, UK | |
| Moderator: Miranda van Tuyl | |
|
|
|
| Auditorium I, Ground Floor | |
| 11:45-12:15 | Test yourself in clinical teratology Quiz |
|
Professor Orna Diav-Citrin & Dr Svetlana Shechtman |
|
| Jerusalem, Israel | |
|
|
|
| 12:15-13:15 | Lunch break |
|
|
|
| 13:15-13:45 | Walk & Talk |
|
|
|
| Mezzanine Floor | |
| 13:45-14:40 | Poster Session |
|
P34. Maternal high therapeutic dose of iodide during breastfeeding: results from the UmbrelLACT study – A contribution from the ConcePTION project Martje Van Neste P35. Tacrolimus exposure in human milk: case series from the UmbrelLACT study – A contribution from the ConcePTION project Martje Van Neste P36. High Dose Estrogen During Breastfeeding – A Prospective Study Shira Shalit P37. Rupatadine during breastfeeding: Two case reports Shira Shalit P38. A Case Report: Niclosamide and albendazole use during the first trimester of pregnancy Mert Kaşkal P39. Pregnancy outcome following exposure to ergotamine tartrate combinations exposure: Preliminary results of 26 cases Mesut Güngör P40. Alcohol, tobacco and illicit drug use before and during pregnancy in Belgium between 2022-2024 Sien Lenie P41. Pregnancy and infant outcomes following prenatal exposure to brivaracetam: a multinational case series from Belgium, the Netherlands and UK Michael Ceulemans P42. Pregnancy outcome following exposure to vaginal fenticonazol in pregnancy: a case report Michael Ceulemans P43. Feasibility of the long term data collection on infant development in the BELpREG registry in Belgium Michael Ceulemans P44. Prevalence and type of paternal medication used in the preconception period in Belgium Michael Ceulemans P45. Prevalence and type of potential teratogenic medications prescribed to hospitalized pregnant women in Belgium Michael Ceulemans P46. Medication adherence during and after pregnancy among women at risk for gestational hypertensive disorders Pauline Dreesen P47. Physicians’ perceptions toward drug administration in pregnancy and package inserts: A qualitative study Mikako Goto P48. Safety of azathioprine and methylprednisolone during breastfeeding: A Case Report Busra Demirci P49. Safety of liragulitid during pregnancy: A Case Report Hakan Ozdemir P50. The use of azathioprine and mercaptopurine during pregnancy is associated with an increased risk of intrahepatic cholestasis of pregnancy Miranda van Tuyl P51. Pregnancy and infant outcomes following the use of asthma medicines with an unknown risk classification Veronique Y.F. Maas P52. Do women experience an increase in milk supply after use of over-the-counter and prescribed galactagogues? Petra Woestenberg P53. Increased risk of mood disorders associated with metoclopramide treatment for nausea and vomiting during pregnancy Veronique Y.F. Maas P54. Treatment of Meniere's disease with betahistine in the first trimester of pregnancy Wolfgang E. Paulus P55. Perinatal Mental Health Issues in Breastfeeding Consultations: Insights from the Japan Drug Information Institute in Pregnancy (J-TIS) Sachi Koinuma P56. Pseudoephedrine use during Pregnancy and the risk for Major congenital malformations: A Large Population-Based Cohort Study Saar Dor P57. The effect of combined contraceptives during breastfeeding on lactation, mothers, and infants- network meta-analysis Shira Shalit P58. Is the use of mesalazine during pregnancy at concern for the fetal kidneys? Corinne Simon P59. Agomelatine exposure during pregnancy: An Australian Observational Cohort Study Susan Kwok P60. Assessing Large Language Models in Clinical Teratology: Preliminary Findings from a Multi-Model Performance Analysis Yusuf Cem Kaplan P61. Register data on neonatal symptoms added to the Swedish knowledge base Janusmed Drugs and Birth Defects Ulrika Nörby P62. Pregnancy-related Adverse Drug Reactions with JAK inhibitors: A Pharmacovigilance Disproportionality Analysis using VigiBase Nazanin Abolhassani P63. Medication use in pregnant women with Polycystic Ovary Syndrome (PCOS): A nationwide cohort study from The Netherlands Veronique Y.F. Maas P64. The MediMama app – the successful implementation of a Dutch mobile app on the safety of over-the-counter medicines during pregnancy and breastfeeding Veronique Y.F. Maas P65. Safety of aripiprazole in first trimester pregnancy: a prospective cohort study Cecilia Lanzi P66. CGRP monoclonal antibodies for migraine and the risk of adverse pregnancy outcomes: Women’s Headache Health - a nationwide registry-based cohort study from 2018 to 2022 Bettina Riedel |
|
| Moderators: Judith Cottin & Debra Kennedy | |
|
|
|
| Auditorium I, Ground Floor | |
| 14:40-16:00 | Oral Communications |
|
14:40-14:50 |
OP1. Pregnancy outcomes associated with first trimester exposure to direct oral anticoagulants: a cohort study |
|
|
Bénédicte Coulm |
|
14:50-15:00 |
OP2. mRNA COVID-19 vaccination in pregnancy and risk of pregnancy loss: a progressive multistate model to account for time-dependent exposure |
|
|
Evelin Beck |
|
15:00-15:10 |
OP3. Papaverine Use during Pregnancy: Findings from a Large Population-Based Cohort Study |
|
|
Sharon Daniel |
|
15:10-15:20 |
OP4. Isotretinoin exposure during pregnancy: a population-based study from Finland |
|
|
Maria Ellfolk |
|
15:20-15:30 |
OP5. Clinical and immunologic evaluation of infants with fetal exposure to immunomodulatory biological agents |
|
|
Karin Nilsson |
|
15:30-15:40 |
OP6. Prescription-based drug use of acetaminophen among pregnant women in Denmark from 2000-2023: A Drug Utilization Study |
| Erika B. Gram | |
|
15:40-15:50 |
OP7. Designing patient information about medicine use in pregnancy for patients from ethnically marginalised groups |
| Amanda Greenall | |
| Moderators: Maya Berlin & Maria Ellfolk | |
|
|
|
| 16:00-16:30 | Coffee break |
|
|
|
| Auditorium I, Ground Floor | |
| 16:30-17:15 | ADHD/ADD medications in pregnancy & lactation (state of the art lecture) |
| Professor Hedvig Nordeng | |
| Oslo, Norway | |
| Moderator: Veronique Maas | |
 |
Angela Lupattelli - In memoriam |
|
|
|
| ** Coffee Breaks & Light Lunches will take place at the Mezzanine Floor (Patio, Mezzanine Floor) | |
|
|
|
| THE MEΤ HOTEL SKY BAR - RESTAURANT | |
| 20:00-23:00 | Conference Dinner |
|
|
|
14.SEPT.2025
| SUNDAY 14th SEPTEMBER 2025 | |
|
|
|
| 09:30-15:00 | Registration Desk Open |
|
|
|
| Auditorium I, Ground Floor | |
| 09:30-11:00 | - Fertility preservation prior to exposure to antineoplastic and other medicines. What is the evidence and what are the consequences to health care systems (State of the Art Lecture) |
| Dr Nicholas Christoforidis | |
| Thessaloniki, Greece | |
| - Treatment of cancer during pregnancy: considerations on the use of antineoplastic agents | |
| Professor Dr Kristel Van Calsteren | |
| Leuven, Belgium | |
| Moderators: Corinna Weber-Schoendorfer & Michael Ceulemans | |
|
|
|
| 11:00-11:30 | Coffee break |
|
|
|
| Auditorium I, Ground Floor | |
| 11:30-12:30 | Oral communications |
|
11:30-11:40
|
OP8. Poor neonatal adaptation after exposure to serotonergic antidepressants during the second or third trimester |
|
|
Maarit K Leinonen |
|
11:40-11:50
|
OP9. Acetaminophen use during pregnancy and the risk of neurodevelopmental disorders in childhood: A Meta-analysis |
|
|
Judith Cottin |
|
11:50-12:00
|
OP10. When Caution Becomes Harmful: Regulatory Overreach in Pregnancy and Lactation During Labeling Across Global Authorities |
|
|
Omer Cohen |
|
12:00-12:10
|
OP11. In utero exposure to acetazolamide and pregnancy outcomes: a cohort study |
|
|
Camille Reinaud |
|
12:10-12:20
|
OP12. Exposure during pregnancy to Il-1 targeted therapies |
|
|
Benoit Marin |
| Moderators: Svetlana Shechtman & Stephanie Padberg | |
|
|
|
| Auditorium I, Ground Floor | |
| 12:30-13:00 | The real-time data system FREIA: a new approach for drug safety in pregnancy |
| Professor Line Kolding | |
| Aarhus, Denmark | |
| Dr Jakob Henriksen | |
| Aarhus, Denmark | |
| Moderators: Mati Berkovitch - Chrysanthi Sardeli | |
|
|
|
| 13:00-13:30 | Meeting end - Farewell |
|
|
|
| 13:30-14:30 | Lunch break |
|
|
|
| * Coffee Breaks & Light Lunches will take place at the Mezzanine Floor (Patio, Mezzanine Floor) | |
